[{"id":"4ba4b07b-a4a4-4a2f-83be-8b39ce10d97d","acronym":"OLYMPIA-1","url":"https://clinicaltrials.gov/study/NCT06091254","created_at":"2023-10-19T17:13:09.646Z","updated_at":"2025-02-25T14:03:56.559Z","phase":"Phase 3","brief_title":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma","source_id_and_acronym":"NCT06091254 - OLYMPIA-1","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • bendamustine • Ordspono (odronextamab)"],"overall_status":"Recruiting","enrollment":" Enrollment 478","initiation":"Initiation: 12/12/2023","start_date":" 12/12/2023","primary_txt":" Primary completion: 04/04/2029","primary_completion_date":" 04/04/2029","study_txt":" Completion: 04/04/2029","study_completion_date":" 04/04/2029","last_update_posted":"2025-02-19"},{"id":"66a34534-4876-4aef-b0bc-743d3e1fef57","acronym":"OLYMPIA-2","url":"https://clinicaltrials.gov/study/NCT06097364","created_at":"2023-10-24T15:13:48.813Z","updated_at":"2025-02-25T15:20:58.496Z","phase":"Phase 3","brief_title":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma","source_id_and_acronym":"NCT06097364 - OLYMPIA-2","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Ordspono (odronextamab)"],"overall_status":"Recruiting","enrollment":" Enrollment 733","initiation":"Initiation: 11/14/2023","start_date":" 11/14/2023","primary_txt":" Primary completion: 07/29/2029","primary_completion_date":" 07/29/2029","study_txt":" Completion: 07/29/2029","study_completion_date":" 07/29/2029","last_update_posted":"2025-02-12"},{"id":"d829b266-c736-4f1b-9200-9489320d1c28","acronym":"OLYMPIA-3","url":"https://clinicaltrials.gov/study/NCT06091865","created_at":"2023-10-19T17:13:17.491Z","updated_at":"2025-02-25T17:39:28.494Z","phase":"Phase 3","brief_title":"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT06091865 - OLYMPIA-3","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Ordspono (odronextamab)"],"overall_status":"Recruiting","enrollment":" Enrollment 904","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 09/18/2028","primary_completion_date":" 09/18/2028","study_txt":" Completion: 09/18/2028","study_completion_date":" 09/18/2028","last_update_posted":"2025-01-29"}]